Carrot Fertility
Carrot runs global fertility benefits and provider networks for employers.
On the record
Checkpoint: Series E financing round or acquisition announcement
The call
Carrot has real employer lock-in and data, but five years without new funding and insurer bundling pressure leave its next financing round as the real test.
Carrot Fertility sells fertility benefits to employers and their workers, handling claims and connecting people to clinics. It has built real advantages that are hard to copy quickly: a database of global claims information, relationships with over 4,200 fertility providers, contracts with more than 1,000 employers, and the regulatory know-how to navigate fertility insurance. These advantages protect it from being replaced by a generic AI tool. However, the company is in financial distress. It has not raised new money in five years, laid off workers twice in recent years, is hiring much less than before, and is losing money. Carrot also faces two major threats: Progyny, a much larger public competitor with billions in market value, is growing faster, and big health insurance companies like UnitedHealthcare and CVS/Aetna are starting to offer fertility coverage themselves as part of their regular plans instead of using outside companies like Carrot. The critical unknown is whether Carrot can raise new money at a fair price, or whether its next funding round will be at a much lower valuation that wipes out shareholder value.
Why
01
AI pressure: General AI chatbots like ChatGPT giving free fertility guidance. Free AI chat can mimic basic fertility navigation, but Carrot uses AI internally via Carrot Intelligence rather than being replaced by it. Could AI do the core job? Unlikely.
02
Bigger players: UnitedHealthcare and CVS/Aetna. Both insurers are bundling fertility modules into standard medical plans, which could make Carrot's standalone benefit redundant for employers. Could a giant copy it? Probably.
03
What protects it. 1,000+ employer contracts, a 4,200-provider network, and global regulatory compliance infrastructure that's hard to replicate quickly.
What would change this call
Carrot announces a Series E or M&A/acquisition deal by Q4 2026. Shows whether investors still back Carrot or whether it is being absorbed/sold.
UnitedHealthcare or CVS/Aetna publicly ships a bundled fertility benefit module. Would show insurers directly competing for Carrot's employer contracts.
Carrot announces another layoff round or reports declining employer contract count. Would show enterprise renewals eroding and financial distress deepening.
UnitedHealthcare or CVS/Aetna publicly ships a bundled fertility benefit module. Would show insurers directly competing for Carrot's employer contracts.
Carrot announces another layoff round or reports declining employer contract count. Would show enterprise renewals eroding and financial distress deepening.
Key numbers
- No institutional funding round in ~59 months
- Valuation estimated near $500M
- Adjusted EBITDA margin around -6%
Named risks
- No new institutional funding since 2021-2022, raising down-round or bridge-financing risk.
- Insurer bundling by UnitedHealthcare and CVS/Aetna could compress enterprise renewal rates.
- Two rounds of layoffs (2022, 2024) and 54% drop in hiring postings in 2025 signal financial strain.
- Low employee sentiment, 3.0/5 Glassdoor rating with only 43% recommend rate as of 2026-05-11.
- Conflicting and largely unverified revenue estimates undermine external assessment of financial health.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Progyny | losing to | Public with market cap over $3B and 6.47M covered lives vs Carrot private, unfunded since 2021, as of 2026-07-01 |
| UnitedHealthcare | contesting | Reportedly integrating fertility modules into medical plans, threatening enterprise renewals within 6-12 months |
| CVS Health/Aetna | contesting | Bundling fertility coverage into medical plans, encroaching on Carrot's benefits-carve-out model as of 2026-03-20 aggregator report |
| Maven Clinic | contesting | Private rival valued at ~$1.35B as of 2025-04-08, broader women's health platform overlapping with Carrot's scope |
| Kindbody | contesting | Owns physical fertility clinics, a structural differentiator versus Carrot's network-only model, per 2025-11-16 CB Insights data |
| Transcarent | gaining on | Bundles Carrot alongside Progyny, Maven, Kindbody, Midi as interchangeable modules since 2025-10-21 |
Questions people ask
- Is Carrot Fertility profitable?
- No verified profitability figures exist since Carrot is private. A third-party SWOT aggregator estimated FY2025 revenue of $118M-$220M with roughly -6% adjusted EBITDA margin, but this is an unverified low-confidence estimate, not an audited disclosure, as of 2026.
- Has Carrot Fertility raised new funding recently?
- No. Carrot's last confirmed round was a $50M Series D closed 2022-08-18 at a post-money valuation of about $611.49M. As of June 2026, roughly 59 months had passed with no new institutional funding reported.
- Is Carrot Fertility laying people off?
- Carrot has had at least two layoff rounds, in 2022 and 2024, per multiple Glassdoor reviews dated through April 2024. Job postings also fell 54.1% in 2025 to just 27, down from 250 in 2023, per Revelio Labs.
- Who is Carrot Fertility's biggest competitor?
- Progyny is Carrot's closest direct competitor, a publicly traded company reportedly with a market cap over $3B and about 6.47 million covered lives across 473 employer clients as of 2026-07-01, dwarfing Carrot's private, unfunded-since-2021 position.
- Could AI replace Carrot Fertility?
- Unlikely to fully replace it. Care navigation and claims triage are automatable and Carrot is automating them itself via Carrot Intelligence (launched 2026-04-16), but its 1,000+ employer contracts, 4,200-provider network, and multinational claims compliance infrastructure are not easily replicated by a generic AI model.
- Who owns Carrot Fertility?
- Carrot Fertility is privately held and venture-backed, with no parent company, per NASDAQ Private Market data dated 2026-06-02. Its largest confirmed investor round was a $75M Series C led by Tiger Global Management in August 2021.
Timeline
- 2026-05-14Carrot expands Sprints AI-native metabolic care program to menopause
- 2026-05-10Carrot announces OB/GYN network expansion targeting rural fertility access gaps
- 2026-04-16Carrot unveils Carrot Intelligence, proprietary AI platform built on ~$1B claims data
- 2026-03-24Carrot launches AI-powered Global Price Monitoring System for billing fraud detection
- 2026-03-18Carrot presents Sprints AI research at US HHS National Conference on Women's Health
- 2025-11-12Carrot announces wearables partnership with ORA and Dexcom Stelo biosensor
- 2025-10-21Carrot joins Transcarent Experience Store alongside Progyny, Maven, Kindbody, Midi
- 2025-08-04Carrot adds 4,200 new clinic and provider contracts across all 50 US states
- 2025-03-12Carrot reportedly partners with Cigna Global Health Benefits unit for fertility offering
- 2022-08-18Carrot closes $50M Series D at ~$611.49M post-money valuation
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Global fertility benefits for employers (2026-06-12)
- Carrot unveils Carrot Intelligence (2026-04-16)
- CB Insights Carrot Fertility Financials (2021-08-16)
- Carrot Fertility 2026 Company Profile
- US fertility startup Carrot raises $75M (2021-10-05)
- Progyny, Kindbody, Carrot, and Maven fertility benefit comparison (2025-04-08)
- Carrot - Headcount, Funding & Open Jobs (2026-06-26)
- Revenue, Competitors, Alternatives (2022-04-19)
- Carrot - Overview, News & Similar companies (2026-07-14)
- Carrot Fertility's Competitors, Revenue... (2025-11-11)
- Carrot Fertility SWOT Analysis
- Carrot Fertility Customers (2025-11-16)